Taris Biomedical LLC
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
- Conditions
- Bladder Cancer TNM Staging Regional Lymph Node (N) N0Bladder Cancer TNM Staging Regional Lymph Node (N) N1Bladder Cancer TNM Staging Primary Tumor (T) T2Bladder Cancer TNM Staging Primary Tumor (T) T2ABladder Cancer TNM Staging Primary Tumor (T) T3Bladder Cancer TNM Staging Primary Tumor (T) T2BBladder Cancer TNM Staging Primary Tumor (T) T3ABladder Cancer TNM Staging Primary Tumor (T) T3BBladder Cancer TNM Staging Distant Metastasis (M) M0
- Interventions
- Drug: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Taris Biomedical LLC
- Target Recruit Count
- 13
- Registration Number
- NCT03518320
- Locations
- 🇺🇸
DuPage Medical Group, Hinsdale, Illinois, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury
- Conditions
- Neurogenic Detrusor Overactivity
- Interventions
- Drug: Trospium-Releasing Intravesical System (TAR-302-5018)
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Taris Biomedical LLC
- Target Recruit Count
- 7
- Registration Number
- NCT03168828
- Locations
- 🇺🇸
Michigan Institute of Urology, Troy, Michigan, United States
🇺🇸Carolinas HealthCare System, Charlotte, North Carolina, United States
🇺🇸Urology of Virginia, Virginia Beach, Virginia, United States
Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder
- Conditions
- Idiopathic Overactive Bladder With Urinary Incontinence
- Interventions
- Drug: Trospium-Releasing Intravesical System (TAR-302-5018)
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Taris Biomedical LLC
- Target Recruit Count
- 43
- Registration Number
- NCT03109379
- Locations
- 🇺🇸
Urology of Virginia, Virginia Beach, Virginia, United States
🇺🇸Medical Center for Clinical Research, San Diego, California, United States
🇺🇸Clinical Research Center of Florida, Pompano Beach, Florida, United States
Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
- Conditions
- Urinary Bladder Cancer
- Interventions
- Drug: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Taris Biomedical LLC
- Target Recruit Count
- 23
- Registration Number
- NCT02722538
- Locations
- 🇺🇸
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer
- Conditions
- Urinary Bladder Cancer
- Interventions
- Drug: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Taris Biomedical LLC
- Target Recruit Count
- 12
- Registration Number
- NCT02720367
- Locations
- 🇳🇱
Radboudumc, Nijmegen, Netherlands
🇳🇱Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands